Sernova Corp (SEOVF) 0.1770 $SEOVF
Sernova Agrees on Terms to Gain Access to Proprietary Stem Cell Technology For the Treatment of Diabetes
Marketwire - Tue Jul 15, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases announced today it has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes.
Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego
Marketwire - Tue Jun 24, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia announced today that it is participating at the US BIO International Convention in San Diego, June 23-26th.
Sernova's CEO Dr. Philip Toleikis Featured on BNN
Marketwire - Fri Jun 20, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia today was featured on BNN by news anchor Francis Horodelski.
Sernova Announces Annual Meeting, Record Date and Adopts Advance Notice By-Law
Marketwire - Wed Feb 26, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and haemophilia is pleased to announce that it will hold an annual general and special meeting of shareholders (the "AGM"
on April 28, 2014. The record date for shareholders entitled to vote at the AGM is March 24, 2014.
Frank Holler Joins Sernova's Board of Directors
Marketwire - Tue Feb 11, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, today announced the appointment of Mr. Frank Holler to its Board of Directors. A Vancouver-based entrepreneur and investor, Holler brings 25 years of success-driven experience in the biopharma and technology sectors to Sernova's board. He has been directly involved in the founding and development of some of Canada's most successful biopharma companies including ID Biomedical, Angiotech Pharmaceuticals and Xenon Pharmaceuticals.
Fission 3 Grants Stock Options
Marketwire - Fri Jan 31, 2:46PM CST
FISSION 3.0 CORP. ("Fission 3" (TSX VENTURE: FUU) announces that it has granted incentive stock options to Directors, Officers, employees and consultants entitling them to purchase up to 14,000,000 shares in the capital of the Company subject to the policies of the TSX Venture Exchange. The options are exercisable until January 31, 2019 at a price of $0.155 per share.
Sernova Announces Appointment of Cathy Steiner as CFO
Marketwire - Fri Jan 31, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA) today announced that Ms. Cathy R. Steiner, CPA CA MSc MBA has joined the Company as Chief Financial Officer.
Financial Press: Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
ACCESSWIRE - Wed Jan 22, 8:00AM CST
(Financial Press - Jan 22, 2014) - Imagine you are a person with diabetes who must focus on measuring your blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring your insulin pump delivery to keep your diabetes under control. And yet, to make matters worse, you still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop your blood sugar levels to dangerous levels without you being aware.
Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
PRWeb - Wed Jan 22, 7:37AM CST
Imagine there is a person with diabetes who must focus on measuring their blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring their insulin pump delivery to keep their diabetes under control. And yet, to make matters worse, they still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop their blood sugar levels to dangerous levels without being aware.
Sernova Corp Engages Ray Matthews & Associates
Marketwire - Wed Sep 11, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), is pleased to announce that it is has engaged Ray Matthews & Associates Inc. ('RM&A' to provide capital markets and advisory services, including investor relations activities.
Sernova and Medicyte to Collaborate on Cell-Based Therapy to Treat Haemophilia
Marketwire - Tue Sep 10, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA) and Medicyte GmbH, today announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte's upcyte(R) cells in Sernova's Cell Pouch(TM) for the treatment of patients with haemophilia A.
Sernova Agrees on Terms to Gain Access to Proprietary Stem Cell Technology For the Treatment of Diabetes
Marketwire - Tue Jul 15, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases announced today it has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes.
Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego
Marketwire - Tue Jun 24, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia announced today that it is participating at the US BIO International Convention in San Diego, June 23-26th.
Sernova's CEO Dr. Philip Toleikis Featured on BNN
Marketwire - Fri Jun 20, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia today was featured on BNN by news anchor Francis Horodelski.
Sernova Announces Annual Meeting, Record Date and Adopts Advance Notice By-Law
Marketwire - Wed Feb 26, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and haemophilia is pleased to announce that it will hold an annual general and special meeting of shareholders (the "AGM"
on April 28, 2014. The record date for shareholders entitled to vote at the AGM is March 24, 2014. Frank Holler Joins Sernova's Board of Directors
Marketwire - Tue Feb 11, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, today announced the appointment of Mr. Frank Holler to its Board of Directors. A Vancouver-based entrepreneur and investor, Holler brings 25 years of success-driven experience in the biopharma and technology sectors to Sernova's board. He has been directly involved in the founding and development of some of Canada's most successful biopharma companies including ID Biomedical, Angiotech Pharmaceuticals and Xenon Pharmaceuticals.
Fission 3 Grants Stock Options
Marketwire - Fri Jan 31, 2:46PM CST
FISSION 3.0 CORP. ("Fission 3"
(TSX VENTURE: FUU) announces that it has granted incentive stock options to Directors, Officers, employees and consultants entitling them to purchase up to 14,000,000 shares in the capital of the Company subject to the policies of the TSX Venture Exchange. The options are exercisable until January 31, 2019 at a price of $0.155 per share. Sernova Announces Appointment of Cathy Steiner as CFO
Marketwire - Fri Jan 31, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA) today announced that Ms. Cathy R. Steiner, CPA CA MSc MBA has joined the Company as Chief Financial Officer.
Financial Press: Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
ACCESSWIRE - Wed Jan 22, 8:00AM CST
(Financial Press - Jan 22, 2014) - Imagine you are a person with diabetes who must focus on measuring your blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring your insulin pump delivery to keep your diabetes under control. And yet, to make matters worse, you still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop your blood sugar levels to dangerous levels without you being aware.
Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
PRWeb - Wed Jan 22, 7:37AM CST
Imagine there is a person with diabetes who must focus on measuring their blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring their insulin pump delivery to keep their diabetes under control. And yet, to make matters worse, they still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop their blood sugar levels to dangerous levels without being aware.
Sernova Corp Engages Ray Matthews & Associates
Marketwire - Wed Sep 11, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), is pleased to announce that it is has engaged Ray Matthews & Associates Inc. ('RM&A'
to provide capital markets and advisory services, including investor relations activities. Sernova and Medicyte to Collaborate on Cell-Based Therapy to Treat Haemophilia
Marketwire - Tue Sep 10, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA) and Medicyte GmbH, today announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte's upcyte(R) cells in Sernova's Cell Pouch(TM) for the treatment of patients with haemophilia A.
